A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome. (March 2023)

• Record Type: Journal Article
• Authors: Hamacher, Rainer; Liu, Xiaofei; Schuler, Markus K.; Hentschel, Leopold; Schöffski, Patrick; Kopp, Hans-Georg; Bauer, Sebastian; Kasper, Bernd; Lindner, Lars; Chemnitz, Jens-Markus; Crysandt, Martina; Stein, Alexander; Steffen, Björn; Richter, Stephan; Egerer, Gerlinde; Ivanyi, Philipp; Kunitz, Annegret; Grünwald, Viktor
• Is Part Of: European journal of cancer. Volume 181(2023)
• Page Start: 145
• Page End: 154
• Publication Date: 2023-03
• Subjects: Soft tissue sarcoma -- Pazopanib -- Doxorubicin -- Frailty -- Elderly -- Geriatric -- Toxicity -- Prognosis -- EPAZ -- Post–hoc; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.12.012
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Objective: The EPAZ study (NCT01861951) showed recently that pazopanib was non-inferior to doxorubicin in patients ≥60 years treated in first line for advanced soft tissue sarcoma . The current post-hoc analysis aimed to assess the prognostic impact of frailty. Methods: Geriatric assessments were evaluated at baseline. Age >75 years, liposarcoma, ECOG = 2, G8 ≤14, instrumental activities of daily living (IADL) ≥1 and Charlson Comorbidity Index ≥2 were tested for their impact on progression-free survival (PFS), overall survival (OS), CTCAE grade 3/4 adverse events (AEs) or serious AEs (SAEs), using univariate and multivariate analysis models. Results: univariate analysis showed an increased risk of grade 3/4 AEs and SAEs for ECOG = 2, G8 score ≤14 or IADL ≥1, independent of treatment. The multivariate analysis exhibited for pazopanib a significantly reduced risk for grade 3/4 AEs (HR 0.53; p = 0.033), and in patients with G8 ≤14 an increased risk for SAEs (HR 2.67; p = 0.011). In the multivariate analysis, G8 ≤14 was a negative prognostic factor for PFS (HR 1.82; p = 0.009) and IADL ≥1 for OS (HR 2.02; p = 0.007). ECOG = 2 was the strongest negative predictor for PFS (HR 4.39; p = 0.001) and OS (HR 3.74; p = 0.004). Neither age nor Charlson Comorbidity Index showed any impact on PFS, OS, incidence of grade 3/4 AEs or SAEs. Conclusions: This post hoc analysis demonstrated that age is not a denominator for outcome or toxicity in elderly patients with soft tissue sarcoma . Instead, geriatric and functional assessments should be used to counsel patients and tailor therapy to individual needs. Moreover, pazopanib has a reduced risk for grade 3/4 AEs compared to doxorubicin. Highlights: Age was not prognostic for outcome or toxicity in elderly patients with advanced STS. Geriatric assessment identified patients at risk for poor tolerability and survival. Pazopanib has a reduced risk for grade 3/4 AEs compared to doxorubicin.